primary dysmenorrhea with vitamin D deficiency primary dysmenorrhea, vitamin D deficiency, VAS score improvement, medical student
Conditions
Interventions
Participants received vitamin D2 at a dose of 20,000 IU, administered as 3 capsules per week for 8 weeks, resulting in a total of 24 capsules.
The investigational product is vitamin D2 (calciferol) at
Experimental Drug,Active Comparator Drug
Treatment arm,Supplement arm
Sponsors
Than Tiathawonchai
Eligibility
Sex/Gender
Female
Age
18 Years to 25 Years
Inclusion criteria
Inclusion criteria: 1.Regular menstruation interval 21-35 days and duration 2-6 days 2.History of dysmenorrhea at least 4 consecutive menstrual cycles within the past 6 cycles 3.Dysmenorrhea meeting the diagnostic criteria for primary dysmenorrhea 4.VAS before receive intervention equal or more than 4 (moderate to severe dysmenorrhea) 5.Presence of vitamin D deficiency (serum 25(OH)D level less than 30 ng/mL)
Exclusion criteria
Exclusion criteria: 1.BMI more than 30 kg/m2 2.Presence of underlying diseases associated with secondary dysmenorrhea such as endometriosis, Leiomyoma, Adenomyosis or other comorbidities including thyroid or parathyroid disease, hypercalcemia, hyperphosphatemia, heart disease, liver disease and kidney disease 3.History of cigarette smoking or alcohol consumption 4.History of previous pregnancy 5.Use of calcium supplements, vitamin D supplements, or other products affecting vitamin D levels within 6 months prior to study enrollment 6.Use of oral contraceptives, intrauterine devices, or other medications containing estrogen or progesterone within 3-6 months prior to study enrollment 7.History of allergy to vitamin D or any vitamin D-containing products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dysmenorrhea severity at 2 and 4 mo Follow up Visual analog score, difference of VAS score | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement rate at 2 and 4 mo Follow up percentage of difference of VAS score before intervention and after intervention,NSIADs Use at 2 and 4 mo Follow up percentage,Adverse event at 2 mo Follow up percentage,Compliance at 2 mo Follow up percentage,vitamin D level at 2 mo Follow up ng/dL | — |
Countries
Thailand
Contacts
Public ContactThan Tiathawonchai
Faculty of Medicine, Khonkean University
Outcome results
None listed